Primary packaging is never an afterthought in the world of injectable drugs, where systems such as vials, syringes, and ...

Astria has made an exclusive licensing agreement with Kaken for the development and commercialisation rights of navenibart in Japan.

The US FDA has given accelerated approval to Jazz Pharma for Modeyso to treat adult and paediatric patients with diffuse midline glioma.

H1 sales growth for Novo Nordisk’s segment that includes Ozempic and Wegovy was down from the same period in 2024.

The FDA has approved a label expansion to Teva’s Ajovy in certain children and adolescents, making it the first migraine prevention drug of its kind in the age group.

Fresenius has entered into a global licensing agreement for the commercialisation of Polpharma vedolizumab biosimilar candidate PB016.

Novo Nordisk has announced the filing of 14 new lawsuits against the sale of unapproved compounded drugs claiming to contain semaglutide.

Spanning topics across R&D, clinical trials, and commercial launch, our podcast series continues as two clinical supplies ...

For the first time in decades, the pharmaceutical industry has been directly affected by a geopolitical trade negotiation between the US and the EU.

While the drugmaker reaffirmed its 2025 revenue guidance of $61bn to $64bn, it raised its full-year 2025 profit outlook. Pfizer now expects to earn $2.90 to $3.10 per share, compared with its previous ...

Agios CEO Brian Goff stated: “The SFDA’s decision marks a significant milestone, as Saudi Arabia becomes the first country to approve Pyrukynd for the treatment of adult patients with thalassemia, ...

The Gates Foundation has announced an investment of $2.5bn to 2030, dedicated to expediting R&D with a focus on improving women's health.